Fundbox Appoints Hilliard Terry to Board of Directors

$UPST
$TGH
$A
$TLGA
Finance: Consumer Services
Finance
Diversified Commercial Services
Consumer Discretionary
Get the next $UPST alert in real time by email

SAN FRANCISCO, CA, June 22, 2021 (GLOBE NEWSWIRE) -- Fundbox, the financial platform for small businesses, announced today that it has appointed Hilliard Terry to its Board of Directors. Mr. Terry is an experienced executive leader, corporate board member and advisor to private equity backed portfolio companies.  

Mr. Terry currently serves on the board of directors of Umpqua Holdings Corporation (NASDAQ:UMPQ), a financial services company. He also serves on the board of directors of Upstart Holdings, Inc. (NASDAQ:UPST), a leading artificial intelligence consumer lending platform, and on the board of TLG Acquisition One Corporation (NYSE:TLGA), a special purpose acquisition company.

"Hilliard is an accomplished public company CFO and a seasoned board member with an impressive record of achievement at the intersection of technology, finance, and banking," said Prashant Fuloria, CEO of Fundbox. "We are thrilled to benefit from his operating and board experience in this time of opportunity and growth post-COVID."

Mr. Terry has recently served as an advisor to private companies and previously as Executive Vice President and Chief Financial Officer of Textainer (NYSE:TGH). Prior to Textainer, Mr. Terry was Vice President and Treasurer at Agilent Technologies (NYSE:A), and was the Head of Investor Relations during their IPO and subsequent spin-off from Hewlett-Packard. Before joining Agilent, he worked in marketing and investor relations for HP's VeriFone subsidiary. Mr. Terry has also held positions in investor relations and investment banking with Kenetech Corporation and Goldman, Sachs & Co., respectively. He is a qualified financial expert with operating experience and in-depth knowledge of accounting, treasury, investor relations, financial planning & analysis, risk management and corporate development.

"Through their AI-powered platform, Fundbox is providing access to credit for a much broader community of small businesses, a sector that has been underserved in the past. This is critically important and fundamentally different from anything that has ever been done before," said Mr. Terry. "There is a massive market opportunity ahead and I look forward to rolling up my sleeves and diving into areas like governance and compliance, which are critical fields of investment for a company at this stage." 

The company is poised for massive growth as the small business economy recovers and expands post-COVID. Recent research has shown that Americans started 4.4 million businesses in 2020, a 24% increase from the year prior, and the first time in history that new businesses have increased during a recession. 

Fundbox provides access to financial tools that enable small business owners to cover business-critical operating expenses. Their AI technology has enabled the company to scale quickly through automation while increasing access to capital through superior predictions and credit decisions. Fundbox's process is fully automated, and 99% of their decisions are made without human intervention.

About Fundbox

Fundbox is a financial platform for small businesses. The company is on a mission to unlock growth for small businesses by providing fast and easy access to financial tools and working capital solutions.  Fundbox has connected with nearly 300,000 businesses, unlocked over $2B in working capital, and invested $100M into its AI platform, gaining deep insights into the small business ecosystem.

The company has received numerous awards including the prestigious Forbes Best Startup Employers and AI 50, Red Herring Top North American 250, CB Insights Fintech 250, and Fintech Breakthrough Awards. Founded in 2013, Fundbox currently has 200+ employees and offices in San Francisco, CA; Dallas, TX; and Tel Aviv, Israel.



Liz Berman
Allison+Partners
908-566-2090
liz.berman@allisonpr.com
Get the next $UPST alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$UPST
$TGH
$A
$TLGA

CompanyDatePrice TargetRatingAnalyst
2/14/2025$12.00 → $70.00Underweight → Equal-Weight
Morgan Stanley
2/12/2025$57.00 → $79.00Underweight → Neutral
Analyst
2/12/2025$49.00 → $105.00Neutral → Buy
B. Riley Securities
2/10/2025$135.00 → $145.00Underweight → Equal Weight
Barclays
12/13/2024$100.00Hold → Buy
Needham
12/3/2024$37.00 → $95.00Neutral → Buy
Redburn Atlantic
12/2/2024Neutral → Underweight
Analyst
11/11/2024Sell → Neutral
BTIG Research
More analyst ratings

$UPST
$TGH
$A
$TLGA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

    Innovative technology supports testing of accuracy and reliability in Autolus Therapeutics' recently approved CAR T therapy AUCATZYL® Agilent Technologies Inc. (NYSE:A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required f

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025

    Agilent Technologies Inc. (NYSE:A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzing tissue samples, often for diagnosing diseases such as cancer. In collaboration with Hamamatsu, PathAI, Proscia, and Visiopharm, Agilent has developed an innovative end-to-end digital pathology workflow. This solution integrates AI-driven precision pathology software

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski

    Scientist recognized for pioneering advances in bioprocess development and biomanufacturing Agilent Technologies Inc. (NYSE:A) today announced that Columbia University has received an Agilent Research Catalyst (ARC) Award on behalf of Dr. Pawel Muranski, an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$UPST
$TGH
$A
$TLGA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$UPST
$TGH
$A
$TLGA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$UPST
$TGH
$A
$TLGA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$UPST
$TGH
$A
$TLGA
Leadership Updates

Live Leadership Updates

See more
  • Broadway Financial Corporation Announces New Board Member

    LOS ANGELES, March 10, 2025 /PRNewswire/ -- Broadway Financial Corporation ("Broadway" or the "Company") (NASDAQ:BYFC), parent company of City First Bank, National Association (the "Bank"), is pleased to announce the appointment of Mary Hentges to its board of directors (the "Board"), effective March 5, 2025, to fill the vacancy on the Board after its size was increased to ten directors. Ms. Hentges will serve on the Audit Committee of the Board of the Company and the Bank, and on the Risk and Compliance Committee and Internal Asset Review Committee of the Bank. Ms. Hentges wi

    $BYFC
    $UPST
    Savings Institutions
    Finance
    Finance: Consumer Services
  • Upstart Appoints Peter Bernard to Its Board of Directors

    Upstart (NASDAQ:UPST), the leading AI lending marketplace, today announced that Peter Bernard has been appointed to the company's Board of Directors. "We're thrilled to welcome Peter to the Upstart Board," said Dave Girouard, co-founder and CEO of Upstart. "Peter's deep expertise in banking and risk management, and rich knowledge of public and private markets, will be particularly valuable as we continue to innovate and expand on the funding side of our business." "Like Upstart, I believe AI is making lending more affordable, inclusive, and transparent," said Bernard. "It's an exciting time in Upstart's evolution and I look forward to helping Dave, Paul, and the team build an enduring com

    $UPST
    Finance: Consumer Services
    Finance
  • Blue Owl Capital and Upstart Partner on Consumer Credit in $2 Billion Agreement

    Upstart (NASDAQ:UPST), the leading artificial intelligence (AI) lending marketplace, today announced a programmatic purchase commitment from funds managed by Blue Owl Capital Inc. ("Blue Owl"). Blue Owl's Alternative Credit strategy will purchase up to $2 billion of consumer loans on the Upstart platform over 18 months. The transaction includes an initial acquisition of a $290 million personal loan portfolio, which closed in September. "We are excited to support Upstart's efforts to make the consumer lending process dramatically more efficient for both borrowers and lenders," said David Aidi, Co-Head of Financial Assets, Blue Owl Alternative Credit. "We are also proud to leverage the Blue

    $OWL
    $UPST
    Investment Managers
    Finance
    Finance: Consumer Services

$UPST
$TGH
$A
$TLGA
Financials

Live finance-specific insights

See more
  • Agilent Reports First-Quarter Fiscal Year 2025 Financial Results

    Delivers solid Q1 results, confirms core growth and EPS for 2025 fiscal year First-quarter fiscal year 2025 Revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% on a core(1) basis compared with the first quarter of 2024. GAAP net income of $318 million; earnings per share (EPS) of $1.11, down 6% from the first quarter of 2024. Non-GAAP(2) net income of $377 million; EPS of $1.31, up 2% from the first quarter of 2024. Outlook for full 2025 fiscal year and Q2 Full-year revenue outlook is now in the range of $6.68 billion to $6.76 billion, representing a range of up 2.6% to 3.8% reported and 2.5% to 3.5% core(1).

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Agilent Announces Cash Dividend of 24.8 Cents per Share

    Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on April 23, 2025, to all shareholders of record as of the close of business on April 1, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted a

    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • Upstart Announces Fourth Quarter and Full Year 2024 Results

    Upstart Holdings, Inc. (NASDAQ:UPST), the leading artificial intelligence (AI) lending marketplace, today announced financial results for the quarter and full year ended December 31, 2024. Upstart will host a conference call and webcast at 1:30 p.m. Pacific Time today. An earnings presentation and link to the webcast are available at ir.upstart.com. "In Q4 of 2024, our business grew dramatically across all product categories, delivered Adjusted EBITDA at levels not seen since the first quarter of 2022, and came within a whisker of returning to GAAP profitability," said Dave Girouard, co-founder and CEO of Upstart. "We launched into 2025 with unparalleled energy and optimism for the future

    $UPST
    Finance: Consumer Services
    Finance

$UPST
$TGH
$A
$TLGA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more